Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
This disclosure features structurally-stabilized and/or cysteine-reactive peptide inhibitors for selective targeting of BFL-1, or dual targeting of BFL-1 and MCL-1. Also disclosed are methods of using such structurally-stabilized and cysteine-reactive peptides in the treatment of BFL-1- and/or MCL-1-expressing or -dependent cancers or diseases of cellular excess (e.g., autoimmune or inflammatory conditions). Also provided are combination therapies comprising such structurally-stabilized and/or cysteine-reactive peptides and inhibitors of the DNA damage response pathway, such as an ATM kinase inhibitor, ATR kinase inhibitor, CHK1/2 inhibitor, or PARP inhibitor; or an inhibitor of MCL-1, or a selective inhibitor of BCL-2, or an inhibitor of BCL-2/BCL-XL, for the treatment of BFL-1-expressing or -dependent cancers (e.g., AML), BFL-1 and MCL-1-expressing or -dependent cancers, or diseases of cellular excess (e.g., autoimmune or inflammatory conditions).
1. A peptide that covalently binds to BFL-1/A1, wherein the peptide comprises the sequence JATX 1 LREFGDX 2 LNFRQ (SEQ ID NO:62), wherein J is an electrophilic warhead; and wherein X 1 is R-octenyl alanine and X 2 is S-pentenyl alanine, and wherein X 1 is cross-linked to X 2 .
2. A peptide that covalently binds to BFL-1/A1, wherein the peptide comprises the sequence JATX 1 LRRAGDX 2 LNFRQ (SEQ ID NO:60), wherein J is an electrophilic warhead; and wherein X 1 is R-octenyl alanine and X 2 is S-pentenyl alanine, and wherein X 1 is cross-linked to X 2 .
3. The peptide of claim 1 , wherein the peptide consists of the sequence of SEQ ID NO:62.
4. The peptide of claim 1 , wherein the electrophilic warhead is a cysteine-reactive acrylamide D-nipecotic acid moiety.
5. The peptide of claim 3 , wherein the electrophilic warhead is a cysteine-reactive acrylamide D-nipecotic acid moiety.
6. The peptide of claim 2 , wherein the peptide consists of the sequence of SEQ ID NO:60.
7. The peptide of claim 2 , wherein the electrophilic warhead is a cysteine-reactive acrylamide D-nipecotic acid moiety.
8. The peptide of claim 6 , wherein the electrophilic warhead is a cysteine-reactive acrylamide D-nipecotic acid moiety.
9. The peptide of claim 1 , wherein the electrophilic warhead is a non-natural amino acid bearing an electrophilic group.
10. The peptide of claim 9 , wherein the non-natural amino acid bearing an electrophilic group has an electrophilic acrylamide or substituted acrylamide linked to the peptide backbone.
11. The peptide of claim 9 , wherein the electrophilic group is selected from the group consisting of: (S)-1-acryloylpyrrolidine-3-carboxamide; 1-acryloylpiperidine-4-carboxamide, (R)-1 acryloylpiperidine-3-carboxamide; (S)-1-acryloylpiperidine-3-carboxamide; (S)-1-acryloylpyrrolidine-2-carboxamide; (R)-1-acryloylpyrrolidine-2-carboxamide; (E)-4-(dimethylamino)but-2-enamide; acrylamide; aziridine, diaziridine, azetidine, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, piperidine, piperazine, morpholine, thiomorpholine, azepaneazirine, diazirine, azete, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, pyridine, diazines, oxazine, thiazine, azepine phenyl (aniline); naphthalene, anthracene, phenanthrene, indole, isoindole, indolizine, quinolone, isoquinoline, quinoxaline, phthalzine, quinazoline, purine, carbazole, indazole, benzimidazole, azaindole, α-cyanoacrylamide, propiolamide, trans 4-dimethylamino-2-butenamide, trans 4-piperidinyl-2-butenamide, a substituted acrylamide, and a vinyl-sulfonamide.
12. The peptide of claim 2 , wherein the electrophilic warhead is a non-natural amino acid bearing an electrophilic group.
13. The peptide of claim 12 , wherein the non-natural amino acid bearing an electrophilic group has an electrophilic acrylamide or substituted acrylamide linked to the peptide backbone.
14. The peptide of claim 12 , wherein the electrophilic group is selected from the group consisting of: (S)-1-acryloylpyrrolidine-3-carboxamide; 1-acryloylpiperidine-4-carboxamide, (R)-1 acryloylpiperidine-3-carboxamide; (S)-1-acryloylpiperidine-3-carboxamide; (S)-1-acryloylpyrrolidine-2-carboxamide; (R)-1-acryloylpyrrolidine-2-carboxamide; (E)-4-(dimethylamino)but-2-enamide; acrylamide; aziridine, diaziridine, azetidine, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, piperidine, piperazine, morpholine, thiomorpholine, azepaneazirine, diazirine, azete, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, pyridine, diazines, oxazine, thiazine, azepine phenyl (aniline); naphthalene, anthracene, phenanthrene, indole, isoindole, indolizine, quinolone, isoquinoline, quinoxaline, phthalzine, quinazoline, purine, carbazole, indazole, benzimidazole, azaindole, α-cyanoacrylamide, propiolamide, trans 4-dimethylamino-2-butenamide, trans 4-piperidinyl-2-butenamide, a substituted acrylamide, and a vinyl-sulfonamide.
15. A pharmaceutical composition comprising the peptide of claim 1 , and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition comprising the peptide of claim 2 , and a pharmaceutically acceptable carrier.
17. A pharmaceutical composition comprising the peptide of claim 3 , and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition comprising the peptide of claim 4 , and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition comprising the peptide of claim 5 , and a pharmaceutically acceptable carrier.
20. A pharmaceutical composition comprising the peptide of claim 6 , and a pharmaceutically acceptable carrier.
21. A pharmaceutical composition comprising the peptide of claim 7 , and a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising the peptide of claim 8 , and a pharmaceutically acceptable carrier.
23. A method of treating a BFL-1/A1-expressing disease or a BFL-1/A1-dependent disease in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of the peptide of claim 1 ; wherein the BFL-1/A1-expressing disease or the BFL-1/A1-dependent disease is a cancer.
24. A method of treating a BFL-1/A1-expressing disease or a BFL-1/A1-dependent disease in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of the peptide of claim 2 ; wherein the BFL-1/A1-expressing disease or the BFL-1/A1-dependent disease is a cancer.
25. The method of claim 23 , wherein the cancer is acute myeloid leukemia (AML).
26. The method of claim 24 , wherein the cancer is AML.